PMID- 22013445
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20211020
IS  - 1687-9112 (Electronic)
IS  - 1687-9104 (Print)
VI  - 2011
DP  - 2011
TI  - Role of factor xa inhibitors in cancer-associated thrombosis: any new data?
PG  - 196135
LID - 10.1155/2011/196135 [doi]
LID - 196135
AB  - The association between cancer and venous thromboembolism (VTE) has been well 
      documented in the literature. Prevention and treatment of VTE in cancer patients 
      is imperative. Typically, the mainstay regimen for VTE prevention and treatment 
      has been anticoagulation therapy, unless contraindicated. This therapy consists 
      of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), factor Xa 
      inhibitor, or vitamin K antagonist (VKA). Current guidelines recommend LMWH over 
      VKA for the treatment of VTE in cancer patients. Factor-specific anticoagulants 
      have been proven safe and effective, and recently factor Xa inhibitors have 
      emerged as a treatment alternative to heparins and VKA. Currently, three factor 
      Xa inhibitors have been identified: fondaparinux (the only one approved so far by 
      the US Food and Drug Administration), idraparinux (in clinical trials), and 
      idrabiotaparinux (in clinical trials). This paper will examine the role of these 
      agents, focusing on fondaparinux, for the prevention and treatment of VTE in 
      cancer patients.
FAU - Zalpour, Ali
AU  - Zalpour A
AD  - Pharmacy Clinical Programs, Division of Pharmacy, The University of Texas MD 
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Kroll, Michael H
AU  - Kroll MH
FAU - Afshar-Kharghan, Vahid
AU  - Afshar-Kharghan V
FAU - Yusuf, Syed Wamique
AU  - Yusuf SW
FAU - Escalante, Carmen
AU  - Escalante C
LA  - eng
PT  - Journal Article
DEP - 20111015
PL  - United States
TA  - Adv Hematol
JT  - Advances in hematology
JID - 101504271
PMC - PMC3195274
EDAT- 2011/10/21 06:00
MHDA- 2011/10/21 06:01
PMCR- 2011/10/15
CRDT- 2011/10/21 06:00
PHST- 2011/07/21 00:00 [received]
PHST- 2011/08/10 00:00 [revised]
PHST- 2011/08/11 00:00 [accepted]
PHST- 2011/10/21 06:00 [entrez]
PHST- 2011/10/21 06:00 [pubmed]
PHST- 2011/10/21 06:01 [medline]
PHST- 2011/10/15 00:00 [pmc-release]
AID - 10.1155/2011/196135 [doi]
PST - ppublish
SO  - Adv Hematol. 2011;2011:196135. doi: 10.1155/2011/196135. Epub 2011 Oct 15.